• PDF / 169,096 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 103 Downloads / 145 Views

DOWNLOAD

REPORT

---

1 S

Grade 3 thrombocytopenia: case report In a study of 63 patients, who had been receiving peptide receptor radionuclide therapy (PRRT) with Lutetium-(177Lu)oxodotreotide, a patient [age and sex not stated] was described, who developed grade 3 thrombocytopenia [indication not stated]. The patient was scheduled to receive 4 cycles of PRRT with Lutetium-(177Lu)-oxodotreotide [Lutetium 177 labelled dotatate] receiving a total dose of 7400 MBq. However, the patient developed grade 3 thrombocytopenia secondary to PRRT [duration of treatment to reaction onset not stated]. At a 4 month follow-up, after the end of fourth cycle, the patient’s thrombocytopenia improved to grade 2. Duan H, et al. Toxicity identification and evaluation of peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NETs). Journal of Nuclear Medicine 61 803514852 (Suppl. 1): no pagination, 1 May 2020. Available from: URL: http://jnm.snmjournals.org/content/61/supplement_1/1442 [abstract]

0114-9954/20/1830-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 14 Nov 2020 No. 1830